Published in Cell Med on October 01, 2011
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med (2000) 18.26
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
International trial of the Edmonton protocol for islet transplantation. N Engl J Med (2006) 13.43
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Five-year follow-up after clinical islet transplantation. Diabetes (2005) 7.86
Immunomodulatory properties of mesenchymal stromal cells. Blood (2007) 6.97
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood (2003) 4.43
Recovery from diabetes in mice by beta cell regeneration. J Clin Invest (2007) 4.32
Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA (2007) 4.29
Current status of clinical islet transplantation. Transplantation (2005) 4.17
Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut (2009) 4.06
Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A (2006) 3.48
Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA (2008) 3.23
Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant (2005) 3.07
Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol (2003) 3.02
Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med (2010) 2.86
Islet transplantation as a treatment for diabetes - a work in progress. N Engl J Med (2004) 2.68
mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes (2008) 2.64
Insulin independence after islet transplantation into type I diabetic patient. Diabetes (1990) 2.57
Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes (2008) 2.25
Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia (2011) 2.20
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol (2009) 2.15
Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell (2010) 2.10
Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res (2010) 2.09
Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes (2009) 1.78
Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest (2008) 1.73
Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes (2010) 1.69
Current advances and travails in islet transplantation. Diabetes (2009) 1.63
Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia (2009) 1.51
Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes (2006) 1.49
Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation (2010) 1.47
Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. Transplantation (2010) 1.44
Graft vascular function after transplantation of pancreatic islets. Diabetologia (2002) 1.42
Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells Dev (2009) 1.40
Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res (2010) 1.35
Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells (2011) 1.35
No evidence for significant transdifferentiation of bone marrow into pancreatic beta-cells in vivo. Diabetes (2004) 1.35
Strategic opportunities in clinical islet transplantation. Transplantation (2005) 1.34
Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant (2007) 1.27
Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation (2007) 1.26
Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun (2009) 1.24
Stem cell therapy for type 1 diabetes mellitus. Nat Rev Endocrinol (2010) 1.21
Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett (2009) 1.20
Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest (2010) 1.18
Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant (2008) 1.17
The choice of anatomical site for islet transplantation. Cell Transplant (2008) 1.17
Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant (2007) 1.13
Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes (2004) 1.13
Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes. Diabetes Metab (2009) 1.12
Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia (2011) 1.11
Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats. Transplant Proc (2009) 1.11
Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant (2008) 1.11
Transplantation of insulin-producing cells derived from umbilical cord stromal mesenchymal stem cells to treat NOD mice. Cell Transplant (2010) 1.10
Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J (2008) 1.03
Failure of transplanted bone marrow cells to adopt a pancreatic beta-cell fate. Diabetes (2006) 1.02
Role of CCL2/MCP-1 in islet transplantation. Cell Transplant (2010) 1.01
Monitoring the survival of islet transplants by MRI using a novel technique for their automated detection and quantification. MAGMA (2009) 0.98
Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant (2006) 0.97
Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes. Rev Diabet Stud (2010) 0.96
Cell biology. To scientists' dismay, mixed-up cell lines strike again. Science (2010) 0.94
Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol Diabetes (2008) 0.93
Brain death in combination with warm ischemic stress during isolation procedures induces the expression of crucial inflammatory mediators in the isolated islets. Cell Transplant (2010) 0.92
Pancreatic islet transplantation: an update. Cell Transplant (2002) 0.92
Islet transplantation: alternative sites. Curr Diab Rep (2010) 0.92
Mesenchymal stem-cell immunosuppressive capabilities: therapeutic implications in islet transplantation. Transplantation (2010) 0.89
Mesenchymal stem cells prevent acute rejection and prolong graft function in pancreatic islet transplantation. Diabetes Technol Ther (2010) 0.89
Comparison of the portal vein and kidney subcapsule as sites for primate islet autotransplantation. Cell Transplant (2008) 0.89
Mesenchymal stem cells protective effect in adriamycin model of nephropathy. Cell Transplant (2008) 0.87
Oxygen tension and blood flow in relation to revascularization in transplanted adult and fetal rat pancreatic islets. Cell Transplant (2002) 0.87
Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells. Clin Exp Immunol (2010) 0.86
Bone marrow and pancreatic islets: an old story with new perspectives. Cell Transplant (2010) 0.85
Pancreatic islet culture and preservation strategies: advances, challenges, and future outlook. Cell Transplant (2010) 0.82
Hepatic artery-portal venous fistula after percutaneous intraportal islet cell transplant. Transplantation (2007) 0.81
Engraftment and growth of transplanted pancreatic islets. Ups J Med Sci (2000) 0.81
Stem cell approaches for the treatment of type 1 diabetes mellitus. Transl Res (2010) 0.80
Immune cell populations in nonhuman primate islets. Cell Transplant (2009) 0.80
Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. Am J Transplant (2007) 0.79
Lack of evidence for recipient precursor cells replenishing β-cells in transplanted islets. Cell Transplant (2010) 0.78